



Sage Therapeutics to Present at Bernstein's 34th Annual Strategic Decisions Conference

May 23, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 23, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at Bernstein's 34th Annual Strategic Decisions Conference on Wednesday, May 30, 2018 at 11:00 A.M. ET in New York, NY.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180523005261/en/>

Source: Sage Therapeutics

Sage Therapeutics

Investor Contact:

Paul Cox, 617-299-8377

paul.cox@sagerx.com

or

Media Contact:

Maureen L. Suda, 585-355-1134

maureen.suda@sagerx.com